A three-physician orthopedics practice and a forty-site orthopedics platform can report the same revenue per physician and be worth different multiples. The difference is not clinical quality. It is what a buyer can do with the earnings after the purchase — and that difference is the entire rollup business.
The arithmetic is called multiple arbitrage, and it is simple enough to state in one sentence: a small practice sells at a small-business multiple, and the same earnings inside a large platform are valued at a platform multiple, because the platform is diversified, has cheaper capital, and can be sold to a larger buyer. Each clinic bought at the lower multiple and folded into the higher-multiple platform creates value on paper the day the deal closes, before any operational improvement. That paper gain is what funds the next acquisition, which is why rollups move in waves rather than one deal at a time.
Paper accretion, though, is not a business. A platform has to centralize something real. The list is consistent across specialties: revenue-cycle management, where denial rates and days in accounts receivable fall when billing moves from a single office to a central team; payer contracting, where a forty-site group negotiates rates a three-doctor practice cannot get a meeting to discuss; recruiting, where an employed model with a real benefits package beats a partnership track that pays out in ten years; credentialing, compliance, and information technology, where one electronic health record and one scheduling system replace a dozen local setups. Platforms that centralize only the logo fail. The ones that centralize the back office keep their physicians, and keeping physicians is the business.
The structure that makes this legal in most states is the management services organization. The MSO owns the non-clinical assets and employs the staff; a professional corporation owned by physicians — the friendly PC — employs the doctors, because most states bar the corporate practice of medicine. Sellers typically take part cash and part rollover equity in the MSO. The rollover is the second bite: if the platform sells later at a higher valuation, the seller profits twice. If it does not, the rollover is paper that never converts, which is why deal structure matters as much as headline price — the subject of the second article in this series.
The cycle has now turned twice in a decade. After the 2023–2024 slowdown, when higher rates reset valuations and deal counts fell, 2025 came back as a record year: Bain & Company counts $191 billion in global healthcare private equity deal value, surpassing the 2021 peak, on 445 buyouts, with provider and related-services deal value up 57% to $62 billion and exit value rebounding to $156 billion from $54 billion in 2024. Physician-practice deal counts tell the same story at the ground level: publicly announced transactions rose from 245 in 2019 to 535 in 2023, according to Irvin Levin's acquisition data. The pipeline refilled because the seller base keeps growing. The American Medical Association counts 42.2% of physicians in private practice in 2024, down from 60.1% in 2012, and the Physicians Advocacy Institute with Avalere counts 82.0% of physicians employed by hospitals or corporate entities as of January 2026. Every independent practice that decides the administrative load is no longer worth it becomes a potential add-on.
What breaks a rollup is rarely the arithmetic. It is physicians leaving after their earnouts end, because the platform never gave them a reason to stay beyond the check. It is a payer renegotiation that claws back the rate uplift the acquisition model assumed. It is integration that never happens because each clinic keeps its own systems, its own billing, and its own culture, leaving the sponsor with a collection of practices and a platform multiple it no longer deserves. And it is antitrust, which now treats a decade of small acquisitions in one city as a single monopolization question — the subject of the third article in this series.
The rollups that survive are the ones whose physicians stay past the earnout, whose payer contracts hold through a renegotiation cycle, and whose back office actually got centralized. That is a management fact, not a financial one, and it is the reason the best rollup brands sell operations first and arbitrage second. A name that says the strategy plainly is a small thing in that story. But in a market where the seller base is every independent practice in America, small things compound: the first call a seller takes is the one from the buyer whose name already told them what the conversation would be about.
Sources: Bain & Company, Global Healthcare Private Equity Report 2026 (global healthcare private equity deal value $191 billion in 2025, surpassing the 2021 peak; 445 buyouts, second-highest on record; provider and related-services deal value $62 billion, up 57% year over year; exit value $156 billion, up from $54 billion in 2024), as reported by Healthcare Dive, https://www.healthcaredive.com/news/private-equity-healthcare-dealmaking-2025-IT-bain-company/809351/. American Medical Association, Physician Practice Characteristics in 2024 (42.2% of physicians in private practice in 2024, down from 60.1% in 2012), https://www.ama-assn.org/print/pdf/node/143251. Physicians Advocacy Institute and Avalere Health, Report on Physician Employment Trends and Practice Acquisitions 2018–2026 (82.0% of physicians employed by hospitals or corporate entities as of January 1, 2026), https://www.physiciansadvocacyinstitute.org/PAI-Research/PAI-Avalere-Health-Report-on-Physician-Employment-Trends-and-Practice-Acquisitions-2018-2026. Irvin Levin, 2024 Health Care Services Acquisition Report (physician-practice transactions 245 in 2019 to 535 in 2023, publicly announced deals only), as summarized by Health Value Group, https://healthvaluegroup.com/trends-in-physician-practice-acquisitions-valuation-multiples/.